


# Rheumatoid Arthritis

## Prevalence in the United States



Source: Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. *Rheumatol Int.* 2017;37(9):1551-1557.

## Cost and Disability Burden

**\$39.2 billion**

Total annual societal costs (direct, indirect, and intangible)



**60%**

of people inadequately treated for RA are **unable to work** 10 years after disease onset



Source: Arthritis Foundation, 2019.

## Current RA Treatment Options

- Nonsteroidal anti-inflammatory drugs (NSAIDs)

- Disease-modifying antirheumatic drugs (DMARDs)



- Corticosteroids

- Biologic response modifiers (biologic DMARDs)

Sources: SEER. Cancer Stat Facts: Leukemia – Chronic Myeloid Leukemia (CML). 2017. Weisberg E, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. *Br J Cancer.* 2006;94:1765-1769.

## Treatment Dissatisfaction

In a cross-sectional survey,

**75%**

of RA patients reported dissatisfaction with their current treatment



Source: Radawski C, Genovese MC, Hauber B, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. *Rheumatol Ther.* 2019;6:461-471.

## Improved Remission With Treat-to-Target Regimen

In a study of early-RA patients:

The percentage of patients achieving Simplified Disease Activity Index remission at 2 years was:

**46%** in the treat-to-target cohort

..... compared with .....

**31%** in the routine care cohort

Source: Brinkmann GH, Norvang V, Norli ES, et al. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study. *Semin Arthritis Rheum.* 2019;48:808-814.